Humanised IgG1 mAb with engineered aglycosylated Fc (N297A) targeting PD-L1. Blocks PD-L1 engagement of PD-1 and B7.1, relieving T cell inhibition. Fc aglycosylation eliminates ADCC/CDC so tumour-infiltrating T cells (which also express PD-L1) are not killed. First PD-L1 inhibitor approved.
Half-Life & Elimination Curve (IV: 27d)
Elimination (IV)
0×t½0h100%(171 mg/L)
1×t½27d50%(85.7 mg/L)
2×t½54d25%(42.9 mg/L)
3×t½81d12.5%(21.4 mg/L)
4×t½108d6.3%(10.7 mg/L)
5×t½135d3.1%(5.36 mg/L)
Elimination t½27d (IV)
Rate Constant (ke)0.00107 h⁻¹
Est. Peak (Cmax)171 mg/L
Clearance (CL)0.00749 L/h
97% Washout (5×t½)135d
Dosing Guidelines
Intravenous (IV): Typical 1200 mg
Pharmacokinetic Parameters
Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 7 L [PMID 27981577]